| Background: Lamotrigine (LTG) has been widely used in the world for its wide range of efficacy for all seizure types and less adverse events since it has been licensed in 1994. A Cochrane systematic review on lamotrigine for refractory epilepsy as adjunctive therapy has published. A number of randomized controlled trials (RCTs) of lamotrigine versus carbamazepine (CBZ) monotherapy for epilepsy have been published in recent years, but their results were not consistent. There is no known systematic review (SR) of lamotrigine versus carbamazepine monotherapy for epilepsy.Objectives: The objective of this review was to compare the efficacy, safety and health-related quality of life (HRQOL) of lamotrigine and carbamazepine to treat partial seizure and generalized tonic-clonic seizure.Material and method: According to the collaborative review group search strategy, we searched the Cochrane Epilepsy Group register for randomized controlled trials published in all languages. We also searched MEDLINE, EMBASE, and the Chinese Biomedical Retrieval System, the RCT/CCT Database of Chinese EBM/Cochrane Center and conference paper databases. In addition, we tracked down the reference lists of papers related to the subject. We searched ten journals (including the Chinese Journal of Neurology) by hand. Two reviewers decided which trials fit the inclusion criteria, graded their methodological quality and collect... |
PDF Full Text Request